Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

NCT04990544 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

528

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: 202-CoV low adjuvant dose
BIOLOGICAL: 202-CoV low antigen dose
BIOLOGICAL: 202-CoV standard dose
BIOLOGICAL: Placebo

Sponsor

Shanghai Zerun Biotechnology Co.,Ltd

Collaborators

[object Object]